“Meaningful improvement will likely take multiple years,” the report said.
While challenges will remain on the investment side through 2023 as weaker cash flow and the need for capital spending amid higher construction costs restricts reserves, the main obstacle facing healthcare systems will be sustained labor costs, S&P said.
There have been some improvements regarding lower use of contract labor but “labor costs remain stubbornly high relative to pre-pandemic levels,” the report said. And even as temporary labor costs may decline, providers have increased pay and compensation to attract and retain full-time nursing staff, measures that “will long remain part of the expense base.”
“These labor pressures, while not accelerating, are also not improving at the rate initially expected and will likely be one of the biggest factors impeding cash flow and margins in 2023 and beyond,” according to the report.
The S&P report adds to similar warnings from Moody’s and Fitch Ratings last month.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
